EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity

Glycogen synthase kinase 3 inhibition lowers PD-1 expression, promotes long-term survival and memory generation in antigen-specific CAR-T cells

(2018) Sadhak Sengupta et al.   CANCER LETTERS

CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas

(2018) Marcus P. Watkins et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha

(2018) Patricia A. Young et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma

(2018) Ayguen Sahin et al.   PLoS One

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

(2017) Anna Minchom et al.   PLoS One

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

(2017) Donald M. O’Rourke et al.   Science Translational Medicine

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade

(2017) Inna Serganova et al.   Molecular Therapy-Oncolytics

Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade

(2017) Evan J. Lipson et al.   Journal for ImmunoTherapy of Cancer

Painting factor H onto mesenchymal stem cells protects the cells from complement- and neutrophil-mediated damage

(2016) Yan Li et al.   BIOMATERIALS

Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma

(2016) Elizabeth D Thompson et al.   GUT

Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma

(2016) Giedre Krenciute et al.   MOLECULAR THERAPY

Epidermal growth factor receptor targeting and challenges in glioblastoma

(2016) Amy Haseley Thorne et al.   NEURO-ONCOLOGY

PD-L1 expression is common and indicates poor prognosis

(2015) Clemens Thoma   Nature Reviews Urology

PD-L1 expression and prognostic impact in glioblastoma

(2015) Edjah K. Nduom et al.   NEURO-ONCOLOGY

Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

(2015) Laura A. Johnson et al.   Science Translational Medicine

Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1

(2015) Krzysztof M. Zak et al.   STRUCTURE

Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma

(2015) Emily Padfield et al.   Frontiers in Oncology

EGFRvIII-Specific Chimeric Antigen Receptor T Cells Migrate to and Kill Tumor Deposits Infiltrating the Brain Parenchyma in an Invasive Xenograft Model of Glioblastoma

(2014) Hongsheng Miao et al.   PLoS One

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results

(2013) Takahiro Oike et al.   PLoS One